查找临床试验
已按「乳腺癌」检索，对应国际通用词 breast cancer
共找到 12 项正在招募的试验（在中国／港澳台设有中心）
数据更新于 09:55，每 5 分钟自动同步Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis
China
年龄 18 Years – 不限
Fudan University
Robustness Evaluation of Deep Inspiration Breath-Hold (DIBH) Plans in Internal Mammary Irradiation
China
年龄 18 Years – 不限
Ruijin Hospital
An In-situ Detection for MicroRNA
China
年龄 18 Years – 75 Years
Tongji Hospital
Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .
China
年龄 18 Years – 75 Years
Hunan Cancer Hospital
Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer
China
年龄 18 Years – 不限
Fudan University
Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer
China
年龄 18 Years – 75 Years
Second Affiliated Hospital, Zhejiang University, School of Medicine
Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer
China
年龄 18 Years – 75 Years
Second Affiliated Hospital, Zhejiang University, School of Medicine
A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC
China
年龄 18 Years – 80 Years
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients
China
年龄 35 Years – 不限
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
United States、Australia、Canada、China、Denmark 等 11 国
年龄 18 Years – 不限
Bayer
A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Cancer
China
年龄 18 Years – 不限
Guangdong Provincial People's Hospital
Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy
China
年龄 18 Years – 80 Years
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University